Inside PD-1/PD-L1,2 with their inhibitors.

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy.
• Understanding their development is crucial for advancing treatment.

Purpose of the Study:

• To review the current state of immune checkpoint inhibitor development.
• To cover both antibody and small molecule approaches.

Main Methods:

• Literature review of recent studies on immune checkpoint inhibitors.
• Analysis of antibody-based and small molecule drug development.

Main Results:

• Significant progress has been made in developing novel ICIs.
• Both antibody and small molecule modalities show promise.

Conclusions:

• Continued research into immune checkpoint inhibitors is vital.
• Development of both antibodies and small molecules will expand therapeutic options.